GTG shares soar on back of Applera lawsuit news
Monday, 20 September, 2004
The share price of Genetic Technologies (ASX: GTG) has risen over 50 per cent since the judge in GTG's lawsuit against Applera ruled largely in the company's favour during the Markman hearing last Thursday.
GTG were up from AUD$0.38 last Thursday to AUD$0.59 at time of writing.
In the hearing, the court examined 15 disputed technical terms within GTG's patent claims, ruling in favour of GTG's definition in 13 cases, and adopting a definition consistent with GTG's position for the other two terms.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
